How do we educate clinicians to ensure appropriate, safe, outcome- and cost-effective deployment of anti-TNF biosimilars in the setting of RA, AS, and related conditions?

How do we educate clinicians to ensure appropriate, safe, outcome- and cost-effective deployment of anti-TNF biosimilars in the setting of RA, AS, and related conditions?

How do we educate clinicians and pharmacists to ensure and facilitate appropriate, safe, outcome- and cost-effective deployment of anti-TNF biosimilars in the setting of RA, AS, and related conditions?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Joseph Markenson, MD

Joseph Markenson, MD

Department of Rheumatology
Department of Medicine
Hospital for Special Surgery, New York, NY
Attending Physician, Hospital for Special Surgery
Professor of Clinical Medicine, Weill Cornell Medical College